- Postdiagnosis low-dose aspirin use in patients with prostate cancer was not associated with lower overall risk for prostate cancer mortality.
- In secondary analysis, low-dose aspirin use was inversely associated with prostate cancer mortality at 5 and 7.5 years postdiagnosis.
Why this matters
- Recent studies suggest a survival benefit with aspirin use in patients with prostate cancer, but study results are inconclusive.
- 29,136 patients with prostate cancer who received low-dose aspirin postdiagnosis (dose, 75-150 mg; ≥2 prescriptions filled within 1 year).
- Funding: Danish Cancer Society.
- 7633 prostate cancer-related deaths were reported during a median follow-up of 4.9 years.
- 24.6% of patients used low-dose aspirin.
- Postdiagnosis low-dose aspirin use was not associated with overall prostate cancer-specific mortality (aHR, 0.95; 95% CI, 0.89-1.01).
- In secondary analysis of extended exposure periods, postdiagnosis low-dose aspirin use was associated with reduction in risk for prostate cancer mortality at 5 years (aHR, 0.91; 95% CI, 0.83-1.01) and 7.5 years (aHR, 0.84; 95% CI, 0.72-0.97).
- Over-the-counter aspirin use was not known.